Cargando…

P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

Detalles Bibliográficos
Autores principales:	Burkart, Madelyn, Khan, Talha, Dinner, Shira, Frankfurt, Olga, Altman, Jessica, Abaza, Yasmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428945/ http://dx.doi.org/10.1097/01.HS9.0000969088.50486.31

Ejemplares similares

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Ven, ven, Lucifer
por: Regueiro
Publicado: (1971)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen
por: Toyama, Daisuke, et al.
Publicado: (2020)

Ven : cursos de español para extranjeros /
Publicado: (1990)

Ven, caballo gris
por: Colina, José de la
Publicado: (2007)

Ven, caballo gris
por: Colina, José de la, et al.
Publicado: (2018)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

Si no te ven no existes
por: Oejo Montano, Eduardo
Publicado: (2004)

Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Ven, caballo gris : y otras narraciones
por: Colina, José de la
Publicado: (1959)

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
por: Wang, Ling, et al.
Publicado: (2018)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

Partial Lipodystrophy and LMNA p.R545H Variant
por: Magno, Silvia, et al.
Publicado: (2021)

P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
por: Russo, Domenico, et al.
Publicado: (2023)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections
por: Labrador, Jorge, et al.
Publicado: (2020)

Así nos ven : 1991, México en la prensa extranjera
Publicado: (1992)

Asi nos ven : 1990, México en la prensa extranjera
Publicado: (1991)

Vistas que no se ven : filmografía mexicana, 1896-1910 /
por: Leal, Juan Felipe
Publicado: (1993)

Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1’(R), 6’(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax
por: Florean, Cristina, et al.
Publicado: (2018)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Ven, caballo gris: Y otras narraciones
por: Colina, José de la
Publicado: (2019)

Ven a leer : material de apoyo para el aprendizaje de la lectura y de la escritura /
Publicado: (1992)

Viaje de ida
por: Gubern, Román

Ida Rodríguez Prampolini
por: Goeritz Álvarez Christian
Publicado: (2019)

Ida y vuelta : entrevistas /
por: Poniatowska, Elena
Publicado: (2017)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Como somos y como nos ven los otros
por: Weinberg, George H.
Publicado: (1996)

miR-545 promotes colorectal cancer by inhibiting transferring in the non-normal ferroptosis signaling
por: Zheng, Sixin, et al.
Publicado: (2021)

De ida y vuelta
Publicado: (2004)

Time series and forecasting with IDA /
por: Roberts, Harry V.
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_l9v5o3t8r3h19lkdj0el1h3bh6